Louis DeGironemo and our experienced nurse practitioner, patients receive individualized treatment plans using advanced GLP-1based therapies designed to support appetite regulation, metabolic function, and overall wellness
Science 122 , 501514 (1955)
Individuals who are pregnant or breastfeeding, those with a history of certain cancers (due to the peptides ability to stimulate blood vessel growth), or those with copper metabolism disorders such as Wilsons disease should avoid this therapy
GLP-1 receptor agonists help increase insulin secretion, decrease glucagon levels, and slow gastric emptying
There are limitations to conventional therapies for melanoma
Having a trusted resource for ongoing education makes you a better partner in your own care